Zhejiang Huahai Pharmaceutical has been granted a patent for a pregabalin lactam methylene dimer and its preparation method, which involves dissolving pregabalin in a solvent, reacting it with an aldehyde in an acidic environment, resulting in a product with high yield, purity, and low cost. GlobalData’s report on Zhejiang Huahai Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zhejiang Huahai Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Zhejiang Huahai Pharmaceutical's grant share as of July 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Pregabalin lactam methylene dimer and its preparation method
The granted patent US12018018B2 introduces a novel compound known as a pregabalin lactam methylene dimer, characterized by a specific structural formula. The patent also outlines a detailed method for synthesizing this compound, which involves a series of steps including the combination of pregabalin, an acid, and an aldehyde in a reaction solvent. The reaction is conducted at temperatures ranging from 30 to 100°C for a duration of 0.5 to 36 hours, ultimately yielding the desired dimer. The claims specify various options for the reaction solvent, acids, and aldehydes, providing flexibility in the synthesis process.
Further claims elaborate on the specifics of the synthesis method, including the preferred molar ratios of the reactants and the optimal temperature and duration for the reaction. The patent details that the reaction solvent can be water, a polar organic solvent, or a combination of both, with examples of suitable solvents provided. Additionally, the patent specifies methods for isolating the pregabalin lactam methylene dimer, such as removing the solvent to obtain a solid and employing techniques like column chromatography for separation. The comprehensive nature of these claims indicates a thorough approach to both the compound's structure and its preparation, potentially paving the way for further applications in pharmaceutical development.
To know more about GlobalData’s detailed insights on Zhejiang Huahai Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
